Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • NPPA fixes retail...

    NPPA fixes retail prices of 14 formulations, check out details

    Written by Ruby Khatun Khatun Published On 2018-03-01T14:42:05+05:30  |  Updated On 1 March 2018 2:42 PM IST
    NPPA fixes retail prices of 14 formulations, check out details

    New Delhi: Through a recent notification, National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India has fixed the retail prices of 14 formulations under the Drugs (Prices Control) Order, 2013 exclusive of goods and services tax (GST).


    The notice states that in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;


    Following are the details







































































































































    Sl. NoName of the
    Formulation / Brand Name
    StrengthUnitManufacturer & Marketing CompanyRetail Price (Rs.)
    (1) (2) (3) (4) (5)(6)
    1Amlodipine +,
    Valsartan Tablet (Valembic 80 AM)
    Each film coated tablet contains:
    Amlodipine Besylate eq. to Amlodipine
    USP 5mg,
    Valsartan USP 80mg Tablet
    1 TabletM/s Vapicare pharma Pvt.
    Ltd. / M/s Alembic
    Pharmaceuticals Limited
    2.10
    2Amlodipine +,
    Valsartan Tablet
    (Valembic 160 AM)
    Each film coated tablet contains:
    Amlodipine Besylate eq. to Amlodipine USP 5mg,
    Valsartan USP 160mg Tablet
    1 TabletM/s Vapicare pharma Pvt.
    Ltd. / M/s Alembic
    Pharmaceuticals Limited
    3.24
    3Paclitaxel (Protein
    Bound Particles) for
    Injectable Suspension
    (Nabtoxol)
    Each vial contains: Paclitaxel 100mg Human albumin1 VialM/s Panacea Biotec Ltd. /
    M/s Mylan
    Pharmaceuticals Pvt. Ltd.
    11115.39
    4Telmisartan +
    Chlorthalidone Tablet
    Each uncoated bilayered tablet contains:
    Telmisartan IP 40mg,
    Chlorthalidone IP 6.25mg
    1 TabletM/s Akums Drugs &
    Pharmaceuticals Ltd. / M/s Mankind Pharma
    Limited
    7.41
    5Glimepiride +
    Metformin +
    Voglibose Tablet
    (TRIVOGO 2/0.3 Mg)
    Each uncoated bilayered tablet
    contains:
    Glimepiride IP 2mg,
    Metformin Hydrochloride IP 500mg
    (As SR form)
    Voglibose IP 0.3mg
    1 TabletM/s Windlas Biotech
    Limited / M/s Alembic
    Pharmaceuticals Ltd.
    9.39
    6Etoricoxib +
    Paracetamol Tablet
    Each film coated tablet contains:
    Etoricoxib IP 60mg , Paracetamol IP 325mg
    1 TabletM/s Ravenbhel Healthcare
    Pvt. Ltd. / M/s Abbott
    Healthcare Pvt. Ltd.
    5.14
    7Sofosbuvir +
    Velpatasvir Tablets
    Each film coated tablet contains:
    Sofosbuvir IH 400mg,
    Velpatasvir IH 100mg
    28’s
    Tablets
    M/s Hetero Labs Ltd. /
    M/s Torrent
    Pharmaceuticals Ltd.
    15625.00
    8Atorvastatin +
    Clopidogrel Capsule
    Each hard gelatine capsule contains:
    Atorvastatin Calcium IP eq. to Atorvastatin 10mg (As Pellets)
    Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)
    1 CapsuleM/s Synokem
    Pharmaceuticals Ltd. /
    M/s Emcure
    Pharmaceuticals Limited
    8.394
    9Atorvastatin +
    Clopidogrel Capsule
    Each hard gelatine capsule contains:
    Atorvastatin Calcium IP eq. to Atorvastatin 20mg (As Pellets)
    Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)
    1 CapsuleM/s Synokem
    Pharmaceuticals Ltd. / M/s Emcure
    Pharmaceuticals Limited
    10.596
    10Rosuvastatin +
    Aspirin +
    Clopidogrel Capsule
    Each hard gelatine capsule contains:
    Rosuvastatin Calcium IP eq. to Rosuvastation 20mg (As pellets)
    Aspirin IP 75mg (As enteric coated
    pellets)
    Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets)
    1 CapsuleM/s Synokem
    Pharmaceuticals Ltd../
    M/s Intas
    Pharmaceuticals Limited
    18.00
    11Ferrous Ascorbate +
    Folic Acid Suspension
    Each 5ml of suspension contains:
    Ferrous Ascorbate eq. to elemental
    Iron 30mg,
    Folic Acid IP 550mcg In a flavoured
    Syrupy base.
    1 MLM/s Innova Captab Pvt.
    Ltd. / M/s Intas
    Pharmaceuticals Limited
    0.647
    12Bortezomib InjectionEach vial contains:
    Bortezomib IP 3.5mg Injection
    1 VialM/s Intas
    Pharmaceuticals Limited
    12500.00
    13Teneligliptin +
    Metformin HCl Tablet
    Each uncoated bilayered tablet
    contains:
    Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg
    Metformin HCl 500mg (SR)
    1 TabletM/s Windlas Biotech
    Limited and marketed by
    M/s Abbott India Limited
    9.62
    14Teneligliptin +
    Metformin HCl Tablet
    Each uncoated bilayered tablet
    contains:
    Teneligliptin Hydrobromide Hydrate
    eq. to Teneligliptin 20mg
    Metformin HCl 1000mg (SR)
    1 TabletM/s Windlas Biotech
    Limited and marketed by
    M/s Abbott India Limited
    10.87


    The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form – III of Schedule – II of the DPCO, 2013 through IPDMS.


    Any manufacturer intending to discontinue production of said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form -IV of Schedule – II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.


    The manufacturers not complying with the ceiling price and notes specified shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.


    Consequent to the issue of ceiling prices of such formulations as specified, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.


    Below is the attachment for the same.


    http://www.nppaindia.nic.in/ceiling/press27feb18/Formulation_Prices(14).pdf


    Medical Dialogues had earlier reported that NPPA had fixed the ceiling prices of 09 formulations under the Drugs (Prices Control) Order, 2013 exclusive of goods and services tax (GST).


    Read also: 9 more formulations including Methylprednisolone Inj under Price Ceiling: NPPA order

    Department of PharmaceuticalsDPCODrugs Prices Control OrderfixesGoods and Services TaxGovernment of IndiaGSTMinistry of Chemicals and FertilizersNational Pharmaceutical Pricing AuthorityNPPARetail PricesScheduled formulations

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok